GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LAVA Therapeutics NV (NAS:LVTX) » Definitions » Construction In Progress

LAVA Therapeutics NV (LAVA Therapeutics NV) Construction In Progress : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is LAVA Therapeutics NV Construction In Progress?


LAVA Therapeutics NV Construction In Progress Historical Data

The historical data trend for LAVA Therapeutics NV's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LAVA Therapeutics NV Construction In Progress Chart

LAVA Therapeutics NV Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Construction In Progress
- - - - -

LAVA Therapeutics NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

LAVA Therapeutics NV Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


LAVA Therapeutics NV (LAVA Therapeutics NV) Business Description

Traded in Other Exchanges
Address
Yalelaan 62, Utrecht, UT, NLD, 3584 CM
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells.

LAVA Therapeutics NV (LAVA Therapeutics NV) Headlines

From GuruFocus

LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer

By Stock market mentor Stock market mentor 02-06-2023

LAVA Announces Annual Meeting of Shareholders

By GlobeNewswire GlobeNewswire 05-30-2023

LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

By Stock market mentor Stock market mentor 01-03-2023